Introductory Paragraph
The COVID-19 pandemic has affected more than 10 million people worldwide with mortality exceeding half a million patients. Risk factors associated with severe disease and mortality include advanced age, hypertension, diabetes, and obesity.1 Clear mechanistic understanding of how these comorbidities converge to enable severe infection is lacking. Notably each of these risk factors pathologically disrupts the lipidome and this disruption may be a unifying feature of severe COVID-19.1-7 Here we provide the first in depth interrogation of lipidomic changes, including structural-lipids as well as the eicosanoids and docosanoids lipid mediators (LMs), that mark COVID-19 disease severity. Our data reveal that progression from moderate to severe disease is marked by a loss of specific immune regulatory LMs and increased pro-inflammatory species. Given the important immune regulatory role of LMs, these data provide mechanistic insight into the immune balance in COVID-19 and potential targets for therapy with currently approved pharmaceuticals.8
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Lokesh Sharma is supported by Parker B Francis Fellowship. Charles Dela Cruz is supported by Veterans affairs Merit Grant (BX004661) and Department of Defense grant (PR181442). Albert Ko and Charles Dela Cruz are supported by a U19 supplement for this work (AI089992-09S2). This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. This work was supported by the Department of Internal Medicine at the Yale School of Medicine, Yale School of Public Health, and the Beatrice Kleinberg Neuwirth Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, Protocol ID. 2000027690). Informed consents were obtained from all enrolled patients. The healthy blood samples were obtained under the protocol (HIC 0901004619) before the onset of COVID-19 outbreak.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is posted and/or available upon request
Abbreviations
- LM
- eicosanoid and docosanoid lipid mediators
- PE
- phosphatidylethanolamine
- LPE
- lyso-PE
- PC
- phosphatidylcholine
- LPC
- lyso-PC
- PS
- phosphatidylserine
- PE(O) or PE(P)
- plasmenyl or plasmanyl plasmalogen
- TAG
- triacylglycerol
- DAG
- diacylglycerol
- MAG
- monoacylglycerol
- CE
- cholesterol ester
- Cer
- ceramide
- DCer
- dihydroceramide
- HCer
- hexosylceramide
- LCer
- lactosylceramide
- SM
- sphingomyelin
- FAC
- frees fatty acid
- Rv
- resolvin
- LX
- lipoxin
- LT
- luekotriene
- HETE
- hydroxyeicosatetraenoic acid
- HEPE
- hydroxyeicosapentaenoic acid
- HDHA
- hydroxydocosahexaenoic acid
- HDPA
- hydroxydocosapentaenoic acid
- PG
- prostaglandin
- PD
- D-series protectin
- TxB2
- Thromboxane B2
- LC-MS/MS
- liquid chromatography tandem mass spectrometry
- CBA
- cytometric bead array
- PCA
- principle component analysis
- PLSDA
- partial least square discriminant analysis
